Truist Securities Maintains Buy on Coherus BioSciences, Lowers Price Target to $20
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Robyn Karnauskas maintains a 'Buy' rating on Coherus BioSciences (NASDAQ:CHRS) but lowers the price target from $22 to $20.
July 14, 2023 | 1:53 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Truist Securities maintains a 'Buy' rating on Coherus BioSciences but lowers the price target from $22 to $20.
The news is directly related to Coherus BioSciences. While the 'Buy' rating is maintained, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100